Both type 1 and type 2 diabetes are burdened with elevated cardiovascular mortality. The risk of developing heart failure (HF) in diabetic patients is two-fold compared to subjects without diabetes. Alterations that lead to HF in Diabetes are not entirely known still today, and so-called diabetic cardiomyopathy is a vague term that refers to myocardial dysfunction in the absence of other concomitant diseases. From a clinical perspective, making diagnosis of HF is still challenging in the early phases. Therapeutic approaches with antidiabetics agents have shown their efficacy for the treatment of HF, while the exact mechanisms how they work are not completely known.

The goal of this Research Topic is to deepen our understanding of the relationship between diabetes and heart failure, encompassing aspects from epidemiology and pathophysiological mechanisms underlying heart failure in individuals with diabetes, to the role of antidiabetic agents in the management of heart failure.

Suitable themes for manuscripts include:

• Epidemiology of type 1 diabetes and heart failure
• Epidemiology of type 2 diabetes and heart failure
• Pathophysiological mechanisms linking diabetes to heart failure
• Diabetic cardiomyopathy in heart failure: insights from type 1 and type 2 diabetes
• The role of novel and established biomarkers in heart failure and diabetes
• Patient-reported outcomes (PROs) in diabetes and heart failure
• The role of SGLT2-inihibitors in heart failure among subjects with diabetes
• The role of GLP1-receptor agonist in heart failure among subjects with diabetes
• The role of finerenone in heart failure among subjects with diabetes
• Prognostic implications in subjects with heart failure and diabetes

Disclosure: Topic Editor Antonio Cutruzzolà has received research grants from Novo Nordisk and Roche.

Are you interested in contributing a manuscript to this Research Topic?

Emerging Insights into the Role of Diabetes in Heart Failure